Early cancer detection startup Navaux gets new funding
![](https://portfolio.investmentguruindia.com/uploads/news/Navaux25.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
US-based cancer detection startup Navaux on Thursday announced receiving fresh funding, which it said, will play a "pivotal role" in entering the Indian market.
The life science company secured an undisclosed investment from angel investor Karna D. Shinde.
This comes as India is rapidly emerging as a hub for health-tech innovations, a trend highlighted by Finance Minister Nirmala Sitharaman's recent announcement in the Union Budget 2024-25, which offers relief to cancer patients by exempting three crucial cancer treatment medicines from customs duty.
"This investment will play a pivotal role in helping Navaux, a company specialising in early cancer detection technology, establish connections within the Indian healthcare industry as they prepare to introduce their cutting-edge solutions to the Indian market," the company said in a statement.
Navaux's innovative ACTIVH test, developed based on preclinical studies, can predict the onset of cancer up to 3-4 years in advance, which can help individuals make lifestyle changes, like quitting smoking and alcohol, to potentially prevent the development of cancer.
Further, ACTIVH is a critical tool for patients undergoing cancer treatments, providing real-time insights into the efficacy of chemotherapy, radiation, or other therapies by monitoring Hepsin levels in the blood. A decrease in Hepsin levels indicates effective treatment, while an increase signals the need for alternative therapies.
"Early cancer detection significantly improves survival rates. Navaux's ACTIVH is a boon for patients and their families. Determining aggressive cancer development before symptoms arise will lead to longer survival and a better quality of life for patients," Shinde said.
"Moreover, biomarkers like Hepsin offer the potential for future therapies that are more effective and produce fewer side effects," he added.
![](https://portfolio.investmentguruindia.com/uploads/news/kotak securities.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/geojit Financial Services.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/TechMahindra23.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/powersector25.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Ajit Mishra.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/fsdkfjeljweoir.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/nirmalasitharaman230717.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Real estate sector_9477.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/global29.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Dollar 30.jpg)
Tag News
![](https://portfolio.investmentguruindia.com/uploads/news/Vikramarka25.jpg)
Telangana presents Rs 2.91 lakh crore Budget with focus on guarantees
![Indexation removal on real estate won't hike tax burden, has limited impact](https://portfolio.investmentguruindia.com/uploads/news/business25.jpg)
![Government looking at bringing down number of customs duty levies to five from about dozen presently: Sanjay Malhotra](https://portfolio.investmentguruindia.com/uploads/news/Economy 12345.jpg)
![Comment on Review of Income Tax Act by Mihir Tanna, Associate Director - Direct Tax at SK Patodia & Associates LLP](https://portfolio.investmentguruindia.com/uploads/news/Mihir Ashok Tanna, Associate Director (Direct Tax) at S K Patodia & Associates.jpg)